High-Value Platform Siloam offers the Optimiser platform with ultra-low volume, cost-effective immunoassay capabilities and existing automation compatibility, presenting a compelling upsell opportunity to labs seeking scalable microfluidic diagnostics.

Point-of-Care Entry TROVA, a single-patient desktop system for point-of-care use, opens doors for direct-to-clinic sales, urgent-care partners, and rural or low-resource settings where rapid testing can drive adoption and recurring consumable revenue.

Multiplexing Expansion Development of a multipatient, multiplexed automated desktop system under NIH contract suggests potential for multi-analyte panels; target collaborations with hospital networks and research labs needing comprehensive panels to expand order size.

Strategic Alternatives Ongoing evaluation of strategic alternatives indicates openness to partnerships, licensing, or potential acquisition; engage with Siloam on co-development, distribution deals, or equity investments to capture near-term opportunities.

Emerging Growth Market Current revenue range and small team size imply room for rapid channel development; propose channel partner programs with distributors serving diagnostics labs, CROs, and academic institutions to accelerate market penetration.